Vertex Pharmaceuticals Inc. (NASDAQ ... While the launch is in its early stages, with over 50 treatment centers activated globally and more than 50 patients having initiated cell collection ...

Journavx, developed by Vertex Pharmaceuticals Incorporated ... in Emergency Medicine and Pain Medicine in San Diego and Vertex Acute Pain Steering committee member. “I believe Journavx could redefine ...

and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a presentation about the business and then a number of other members of the ...

Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert therapeutic changes into the genome, today ...

Net revenues of $25.1 million in Q1 2025, a 29% increase compared to $19.5 million in Q1 2024, driven by strong demand for Cannara's premium-grade cannabis products.Record Market Share: Achieved ...

Bain Capital proposes to take Surgery Partners private Akero Therapeutics shares gained 117% in early trading on Monday ... CVS adds four new board members in deal with Glenview as CEO pursues ...

Some of the larger M&A deals of 2024 were Eli Lilly’s buyout of Morphic, Vertex’s buyout ... of the Zacks Rank of all the member stocks. The Zacks Large Cap Pharmaceuticals industry currently ...

Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean ... and Capital International Investors since early 2014. Longest-tenured manager Alan Berro, who ...